Thus, targeting the NOTCH3 pathway may be a promising therapeutic strategy for human aortic elastinopathies (i.e., nonsyndromic SVAS and WBS), which are caused by ELN haploinsufficiency and generally lack lung parenchymal disease. This evidence concerns the gene NOTCH3 and Williams syndrome.